EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Klebsiella pneumoniae and Pseudomonas aeruginosa MAPS vaccine combining O polysaccharides and pathogen-specific proteins

Mohammed N Amin, James E Sinclair, Brittany Curtis, Lada Sycheva, Heather Fox, Myeong-Jin Choi, Surekha Shridhar, Jacqueline Kolasny, Joseph Nkeze, Ethel Apolinario, Sang Hyun, Nicolas Hegerle und 14 weitere

mBio · 2025

DOI: 10.1128/mbio.00807-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2025. Verfasst von Mohammed N Amin und 25 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Pseudomonas aeruginosa, Klebsiella Infections, Pseudomonas Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Klebsiella pneumoniae (KP) and Pseudomonas aeruginosa (PA) are leading causes of healthcare-associated and community-acquired infections. Despite decades of efforts, there are no licensed vaccines for either pathogen. The surface O polysaccharides (OPS) of Klebsiella pneumoniae and Pseudomonas aeruginosa are essential virulence factors for these bacteria and are targets of protective antibacterial antibodies. The multiple antigen presenting system (MAPS) vaccine platform was used to create a multivalent Klebsiella / Pseudomonas vaccine in which the surface OPS of four Klebsiella and eight Pseudomonas strains were linked to a high MW biotinylated Klebsiella oxytoca (KO) K19 capsular polysaccharide backbone and subsequently linked to pathogen-specific fusion proteins, consisting of Klebsiella MrkA, the Pseudomonas flagellin B D2 subunit, and PcrV. We show here that these MAPS complexes incorporating KP and PA OPS, as well as pathogen-specific proteins, were highly immunogenic in rabbits and mice and induced functionally active antibodies in vitro and in murine animal models. IMPORTANCE Infections caused by Klebsiella pneumoniae (KP) and Pseudomonas aeruginosa (PA) are widely recognized to be of “urgent” and “serious” concern, in part because of their widespread antimicrobial resistance. To date, there is no licensed vaccine for either pathogen. We developed a novel multiple antigen presenting system (MAPS) vaccine platform that contains eight O polysaccharides (OPS) of PA and four OPS of KP, which will cover over 80% of clinical infections with these pathogens. In addition, this vaccine includes three pathogen-relevant proteins acting both as carrier proteins to provide T cell help for these polysaccharides as well as to elicit functionally active antibodies that may also protect against KP and PA infection. The use of pathogen-relevant proteins that may contribute to vaccine efficacy in place of the more traditional carrier proteins is a novel concept. The MAPS vaccine platform also generates Th17 and Th1 responses. This KP/PA MAPS vaccine may prevent infection with these pathogens and reduce their transmissibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella pneumoniaePseudomonas aeruginosaKlebsiella InfectionsPseudomonas InfectionsBacterial ProteinsO AntigensBacterial VaccinesPolysaccharides, BacterialPseudomonas VaccinesAnimalsMiceRabbitsAntibodies, BacterialFemaleAntigens, BacterialVirulence Factors

Stichwörter der Autor:innen

Klebsiella pneumoniaeMAPS vaccineMrkAO polysaccharidePcrVPseudomonas aeruginosaflagellin

Substanzen

Antibodies, BacterialBacterial ProteinsO AntigensBacterial VaccinesPolysaccharides, BacterialPseudomonas VaccinesAntigens, BacterialVirulence Factors

Autor:innen und Institutionen

  • Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Affinivax Inc. (a GSK company), Cambridge, Massachusetts, USA.
  • RRD International, Rockville, Maryland, USA.
  • Nosocomial Vaccines Company, Rockville, Maryland, USA.
  • Siber Biotechnologies LLC, New York, New York, USA.

ORCID-Profile: Marcela Pasetti, Richard Malley, Sharon M Tennant, Alan Cross

Förderung

  • Astellas Pharma

Zitieren

APA

Amin, M. N., Sinclair, J. E., Curtis, B., Sycheva, L., Fox, H., Choi, M. J., Shridhar, S., Kolasny, J., Nkeze, J., Apolinario, E., Hyun, S., Hegerle, N., Sen, S., Permala Booth, J., Leney, M., Molrine, D., Saia, G., Pasetti, M., Broering, T., …, & Cross, A. (2025). Novel Klebsiella pneumoniae and Pseudomonas aeruginosa MAPS vaccine combining O polysaccharides and pathogen-specific proteins. mBio. https://doi.org/10.1128/mbio.00807-25

Vancouver

Amin MN, Sinclair JE, Curtis B, Sycheva L, Fox H, Choi MJ, et al. Novel Klebsiella pneumoniae and Pseudomonas aeruginosa MAPS vaccine combining O polysaccharides and pathogen-specific proteins. mBio. 2025. doi:10.1128/mbio.00807-25

BibTeX
@article{Amin2025,
  author = {Amin, Mohammed N and Sinclair, James E and Curtis, Brittany and Sycheva, Lada and Fox, Heather and Choi, Myeong-Jin and Shridhar, Surekha and Kolasny, Jacqueline and Nkeze, Joseph and Apolinario, Ethel and Hyun, Sang and Hegerle, Nicolas and Sen, Shaichi and Permala Booth, Jasnehta and Leney, Mark and Molrine, Deborah and Saia, Greg and Pasetti, Marcela and Broering, Teresa and Michon, Francis and Malley, Richard and Siber, George R and Tennant, Sharon M and Ambrosino, Donna and Simon, Raphael and Cross, Alan},
  title = {Novel Klebsiella pneumoniae and Pseudomonas aeruginosa MAPS vaccine combining O polysaccharides and pathogen-specific proteins},
  journal = {mBio},
  year = {2025},
  doi = {10.1128/mbio.00807-25}
}
Kostenlos starten →